ITM

ITM to Present Phase III COMPOSE Poster and Host Satellite Symposium on Radiotheranostics in NET cancer at ENETS Conference

Retrieved on: 
Thursday, March 16, 2023
Conference, Therapy, Division, NETS, Endocrine oncology, Vall d'Hebron University Hospital, ITM, University of Utah, Professor, Gastrointestinal tract, NET, Patient, III, GEP-NET, History, Nuclear medicine, Huntsman Cancer Institute, Biomarker, Doctor of Philosophy, Hospital trust, Associate professor, University, Medical imaging, MD

COMPOSE evaluates the company’s lead radiopharmaceutical candidate, ITM-11 (n.c.a.

Key Points: 
  • COMPOSE evaluates the company’s lead radiopharmaceutical candidate, ITM-11 (n.c.a.
  • 177Lu-edotreotide) compared to standard of care in patients with well-differentiated high grade 2 and grade 3 somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (G2+G3 SSTR+ GEP-NETs).
  • ITM will also host a hybrid in-person and virtual radiotheranostics satellite symposium titled “Transforming the Therapeutics Landscape for Neuroendocrine Tumors” featuring presentations and discussions between leading endocrine oncology and nuclear medicine clinicians and researchers.
  • ITM will host a medical exhibition booth, as well as a virtual booth during the conference.

ITM, Helmholtz Munich and University Hospital Münster Announce Start of Phase I Clinical Trial with Radiotherapeutic ITM-31 for Glioblastoma

Retrieved on: 
Monday, March 13, 2023
Nuclear medicine, Recurrence, IIT, Risk, ITM, Glioblastoma, Cancer, Hospital, Patient, Brain, Neoplasm, Teaching hospital, Survival, Pharmaceutical industry, Medical imaging, Vaccine, Neurosurgery

ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment developed by Helmholtz Munich coupled with ITM's medical radioisotope, non-carrier-added lutetium-177 (n.c.a 177Lu, EndolucinBeta®).

Key Points: 
  • ITM-31 is a carbonic anhydrase (CA) XII-specific antibody Fab fragment developed by Helmholtz Munich coupled with ITM's medical radioisotope, non-carrier-added lutetium-177 (n.c.a 177Lu, EndolucinBeta®).
  • The investigator-initiated trial (IIT) is sponsored by the University Hospital Münster, conducted in hospitals in Münster, Essen, Cologne, Würzburg, and supported by ITM and Helmholtz Munich.
  • Intracavitary Radionuclide Therapy with ITM-31 could provide such a treatment opportunity,” says Prof. Walter Stummer, Principal Investigator and Chairman of the Department of Neurosurgery at the University Hospital Münster.
  • This trial is an important first clinical step to developing ITM-31 into a drug potentially capable of circumventing previous hurdles in this high-need indication.”

Tradition and Innovation Collide at Decentraland’s Metaverse Fashion Week

Retrieved on: 
Monday, February 27, 2023
Metaverse, Kraken, Vivienne Westwood, Fashion week, Pizzeria, Culture, PwC, Digital, House, Music, OVER, Teatro Colón, Yoga, Spatial, Wearable, UME, Digital fashion, Fabricant, Name, Meditation, HAPE, Woman, Exhibition, DKNY, Amorepacific Corporation, The Walls Group, Collection, Partnership, Pinko, NFT, Opera, Vuelta, Singapore, STEM, AR, Paris Fashion Week, 3D, Clarks, Vogue Singapore, Miami Fashion Week, Emote, ITM, Nightclub, Video game, Fashion design, Film industry, Cryptocurrency, Consumer electronics, Entertainment, Hatmaking, Industrial design, Decentraland, Wearable computer

“This year we are honored to continue the legacy of Metaverse Fashion Week.

Key Points: 
  • “This year we are honored to continue the legacy of Metaverse Fashion Week.
  • We are seeing the return of many fashion houses, and also the refinement and elevation of digitally-native fashion.
  • The curatorial theme Future Heritage of MVFW23 is dedicated to engaging digital designers with fashion institutions, and illuminating the connection between innovation and tradition.
  • Miami Fashion Week (MIAFW) became the first globally recognized Fashion Week to participate in a digital fashion week.

HPA 2023: Advanced HDR by Technicolor Offers Efficient and Cost-Effective Path to Enhancing Production and Distribution of Live, Episodic and Theatrical Content

Retrieved on: 
Tuesday, February 21, 2023
Television, Library, Mitchell, SDR, HPA, Sport, HDR, Education minister, Philips, ITM, PALM, InterDigital, Environment, Advertising, SL, Cassette tape, Tourism, Marketing, Technicolor

"HDR is already a mainstream element in the development of episodic and cinematic productions, which is why analysts at Allied Market Research are projecting that the high dynamic range market will reach $126.74 billion (US) by 2030," says Gordon. "High dynamic range -- and many of the immersive formats we're seeing emerge in the industry -- amplify the creative palette. This ultimately results in a more immersive and impactful experience."

Key Points: 
  • "High dynamic range -- and many of the immersive formats we're seeing emerge in the industry -- amplify the creative palette.
  • HDR specifically enables a broader range of colors and brightness offering new ways to control the viewing experience much more succinctly on screen.
  • "It is important to understand the available content and the devices content providers and developers want to target.
  • Another critical factor to consider while conducting these conversions is the ability to preserve the creative intent of the content.

CNL’S Vision to Become a World Leader in Actinium-225 is Coming to Life

Retrieved on: 
Thursday, February 2, 2023
Nuclear medicine, Nuclear, Good laboratory practice, Atomic Energy of Canada Limited, Safety, International, Atomic energy, Cancer, Triangle Universities Nuclear Laboratory, CNL, ITM, Active ingredient, TAT, Isotope, Teva Active Pharmaceutical Ingredients, Actinium-225, Hope, API, Chalk River Laboratories, Radiobiology, Radiopharmaceutical, Alpha particle, Research, Fine chemical, Medical imaging

CHALK RIVER, Ontario, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology laboratory, is celebrating a key milestone in its vision to become a world leader in the research and production of Actinium-225, a promising but very rare medical isotope. The end of 2022 marked five years since the first successful shipment of Actinium-225, and CNL has been shipping this product successfully and reliably ever since, which recently included its 100th shipment. Furthermore, CNL has realized steady progress during that same time, including establishing research-scale production facilities at the Chalk River Laboratories campus, implementing international standards to perform pre-clinical research at the site, and securing a global network of partners needed to eventually deliver a stable, commercial supply of the isotope.

Key Points: 
  • CNL is now working to position itself as a world leader and international hub for targeted alpha therapy (TAT) and for the production of the extremely rare and promising Actinium-225 isotope.
  • Both of these accomplishments position CNL to advance research related to TAT and Actinium-225 on its campus and using its own materials.
  • As Actinium-225 decays, it emits high-energy alpha particles that effectively kill cancer cells, leaving nearby healthy cells unharmed in the process.
  • To learn more about CNL, including its work in health sciences, please visit www.cnl.ca .

b1BANK Announces Plans to Relocate and Expand Downtown Lake Charles Banking Center

Retrieved on: 
Thursday, January 19, 2023
Economic development, Rouge, Growth, Pacific typhoon season, Lake, ITM

Baton Rouge, LA, Jan. 19, 2023 (GLOBE NEWSWIRE) --  b1BANK today announced plans to relocate its Ryan Street location to a new building in downtown Lake Charles later this year.

Key Points: 
  • Baton Rouge, LA, Jan. 19, 2023 (GLOBE NEWSWIRE) --  b1BANK today announced plans to relocate its Ryan Street location to a new building in downtown Lake Charles later this year.
  • The bank has been a part of the Lake Charles community since 2009.
  • “We have experienced significant growth in the Lake Charles market and require a larger facility to better serve our current clients’ needs and the community,” said Jeffrey Davis, market president, b1BANK.
  • “The building design will reflect some of the historic architecture of the downtown area,” said Matt Redd, developer, Redd Properties.

SRM Predicts FIs to Focus on Deposits and Investing in Fintech and ITMs in 2023

Retrieved on: 
Wednesday, January 11, 2023
Technology, Other Communications, Finance, Fintech, Public Relations, Investor Relations, Marketing, Banking, Other Technology, Communications, Professional Services, American Bankers Association, HSBC, Digital, The, Pressure, ITMS, Marketing, Financial technology, JPMorgan Chase, Research, Diving, ITM, Investment, Management, Bank, Cryptocurrency, SRM

Financial institutions must have comprehensive plans for retaining and attracting revenue producers when there is upward pressure on wages.

Key Points: 
  • Financial institutions must have comprehensive plans for retaining and attracting revenue producers when there is upward pressure on wages.
  • Institutions must have a deeper awareness and understanding of the fintech market.
  • Competition for deposits will be a significant focus for banks and credit unions in 2023, forcing many to use tried-and-true methods and new approaches to ensure depositors stay in the fold.
  • “This year, the most successful institutions will focus on what will most effectively help them attract and retain customers.

Provectus Biopharmaceuticals Releases 2023 Stockholder Letter

Retrieved on: 
Monday, January 9, 2023
Disease, OS, RECIST, Knowledge, SOC, CR, CRS, Melanoma, Cancer, University, Dermatology, Particle-size distribution, Orphan Drug Act of 1983, H. Lee Moffitt Cancer Center & Research Institute, RCT, RBS, Cumming School of Medicine, Metastasis, Combination therapy, CB, SEER, Research, ITM, ORR, Hematology, III, Incidence, Progression-free survival, Classification, PFS, Neoplasm, Rockefeller University, AJCC, Infection, Prevalence, Lymph, Meta-analysis, Clinical trial, PV-10, Cell death, Standard of care, Safety, Vaccine, Diagnosis, PRN, Survival, Patient, Pembrolizumab, Medical device, Pharmaceutical industry, Medical imaging, Television, Veterinary medicine, Epidemiology, Medicine

This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.

Key Points: 
  • This effort has been utilizing Provectus’ clinical efficacy data from approximately 180 in-transit melanoma (ITM) patients treated with single-agent PV-10, as well as safety data from more than 300 melanoma patients.
  • ITM diagnosis is specifically associated with an overall poor prognosis and has the potential to be seriously debilitating and life threatening.
  • Furthermore, we encourage collaboration between our various researchers to assist Provectus in building the Company’s medical science platform and associated drug pipeline.
  • Provectus’ capital raising efforts will continue in 2023.

ITM to Present at the 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Tuesday, January 3, 2023
Conference, CFO, ITM, PST, Garching (Munich U-Bahn), Nightclub

Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points: 
  • Garching / Munich, January 03, 2023 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that CEO Steffen Schuster and CFO Dr. Klaus Maleck will participate in the 41st Annual J.P. Morgan Healthcare Conference in San Francisco.
  • Steffen Schuster will present a corporate overview on Monday, January 9, 2023, at 8:00 am PST.

ITM showcases the world's first EV dNFT to achieve trust from edge of vehicle history reports

Retrieved on: 
Friday, January 6, 2023
MIH, ESG, Architecture, EV, CES, Web3, OTA, EVS, DID, NFT, ITM, Blockchain, Insurance, Maintenance, Hand, Mobility, Foxconn, Environment, Cryptocurrency, Renewable energy

It would make data such as the vehicle's maintenance and trade history tamper-proof, and ensure that the vehicle owner controls and owns trustworthy and legitimate information.

Key Points: 
  • It would make data such as the vehicle's maintenance and trade history tamper-proof, and ensure that the vehicle owner controls and owns trustworthy and legitimate information.
  • "Currently, car manufacturers use traditional static NFT technology which binds data to a central database outside the blockchain.
  • "Electric vehicles generate a large amount of digital data, and the data is exactly what makes EVs valuable," Chen explained.
  • The data could be downloaded and verified through the dNFT bound to the EV.